TrialCardiovascular diabetology2025

Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.

Sean Wharton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.